RecruitingPhase 2

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

United States56 participantsStarted 2026-06-17

Plain-language summary

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adult patients (18+) on mechanical ventilations with acute respiratory distress syndrome (ARDS) by Berlin Criteria (≤48 hours)
. P:F ratio \< 300
. Positive end-expiratory pressure (PEEP) ≥5 cm H2O
. Bilateral opacities on chest x-ray or chest computerized tomography (CT)-- not fully explained by effusions, lobar/lung collapse, or nodules
. Respiratory failure not fully explained by cardiac failure or fluid overload
. Within 1 week of known clinical insult or new or worsening respiratory symptoms
. Patient or Legal authorized representative able to understand and give written informed consent

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Day 4 Oxygenation Index

Timeframe: Day 1 through Day 4

Trial details

NCT IDNCT06513949

SponsorImplicit Bioscience

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-03-01

Contact for this trial

Linzee Mabrey, MD, MSc

(206) 897-5051 mflinzee@uw.edu

View on ClinicalTrials.gov More Acute Respiratory Distress Syndrome trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adult patients (18+) on mechanical ventilations with acute respiratory distress syndrome (ARDS) by Berlin Criteria (≤48 hours)
. P:F ratio \< 300
. Positive end-expiratory pressure (PEEP) ≥5 cm H2O
. Bilateral opacities on chest x-ray or chest computerized tomography (CT)-- not fully explained by effusions, lobar/lung collapse, or nodules
. Respiratory failure not fully explained by cardiac failure or fluid overload
. Within 1 week of known clinical insult or new or worsening respiratory symptoms
. Patient or Legal authorized representative able to understand and give written informed consent

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

Exclusion criteria